SIRIC - Cancérologie Marseille

SIRIC Marseille

Gliomes

Coordinatrice D. Figarella-Branger. Coordinateur adjoint O. Chinot

Les gliomes sont les cancers du système nerveux central (SNC) les plus fréquents et regroupent plusieurs sous-types histologiques de tumeurs et plusieurs degrés de malignité. Les glioblastomes (GBM) sont la forme la plus commune et la plus maligne. Les GBM sont très invasifs et angiogéniques ; ils sont le plus souvent résistants au traitement et ne peuvent pas être traités par la chirurgie uniquement.

Malgré des progrès récents qui permettent maintenant une survie à 5 ans pour 10% des patients atteints de GBM, la survie médiane n’est que de 15-18 mois. Des avancées récentes importantes sur le front de la caractérisation moléculaire des gliomes ont permis l’identification de biomarqueurs qui permettent une meilleure classification des tumeurs cérébrales. Mais de nouveaux marqueurs pronostiques et prédictifs de la réponse aux traitements sont encore nécessaires.

La mise au point de thérapies plus efficaces et induisant moins d’effets secondaires nécessite l’identification de nouvelles cibles thérapeutiques. Une meilleure comprehension de la biologie des gliomes et des effets des traitements permettra la mise en oeuvre d’études précliniques dans des modèles in vitro ou murins combinés à des approches d’imagerie multi-modale. Notre priorité reste avant tout d’améliorer la qualité de vie et la réinsertion socio-professionnelle des patients.

Chaque année 250 adultes et 50 enfants sont orientés vers l’AP-HM pour le traitement d’un gliome ; le département de neuro-oncologie adulte a une file active de 700 patients/an. Des collections de tissus fixés ou congelés destinées aux analyses sont stockées dans la biothèque de l’AP-HM. Ces échantillons sont associés aux données cliniques de plus de 2 000 patients. Un réseau a été organisé qui rassemble les compétences scientifiques et cliniques sur les glioblastomes ainsi que plusieurs plateformes technologiques.

Le SIRIC est une opportunité pour ces équipes d’optimiser leurs recherches pour améliorer la compréhension de la maladie, mettre au point des approches thérapeutiques innovantes et améliorer la prise en charge des patients atteints de gliomes. Notre réseau rassemble des équipes cliniques dans le champ de la neuro-oncologie, des biologistes moléculaires, des chercheurs spécialistes de la biologie des tumeurs mais aussi de l’imagerie, de la neuro-cognition et des sciences sociales, qui constituent une masse critique interdisciplinaire pour atteindre nos objectifs de :

  1. identifier des marqueurs préopératoires qui pourraient guider la chirurgie, des marqueurs diagnostics et caractériser les modifications génétiques qui conduisent à l’initiation et à la progression du processus tumoral ;
  2. étudier la relation entre la tumeur et le cerveau en particulier en termes de connectivité fonctionnelle du cerveau à proximité de la tumeur, étudier la biologie des gliomes et identifier de nouvelles cibles thérapeutiques potentielles ;
  3. améliorer l’évaluation de nouvelles drogues/stratégies thérapeutiques ;
  4. et étudier la neuro-cognition et la qualité de vie des patients.

PNG

Equipe 1 : Service de Neurochirurgie Adulte (Prs H. Dufour, JC. Peragut, PH. Roche, J. Regis, P. Metellus, Pôle Neurosciences, AP-HM)
Equipe 2 : Service de Neurochirurgie Pédiatrique (Drs G. Lena and D. Scavarda, Pôle de chirurgie pédiatrique, AP-HM)
Equipe 3 : Service d’Anatomie Pathologique et Neuropathologie (Pr D. Figarella-Branger, Pôle Oncologie, AP-HM)
Equipe 4 : Service de Transfert d’Oncologie Biologique (Pr L’H.Ouafik, Dr I. Nanni-Metellus, Pôle Oncologie, AP-HM)
Equipe 5 : Tumorothèque de l’AP-HM (Pr D. Figarella-Branger, Pôle Oncologie, AP-HM)
Equipe 6 : Service de Neuroradiologie (Pr N. Girard, Pôle imagerie, AP-HM)
Equipe 7 : Médecine nucléaire (Prs O. Mundler, E. Guedj, Pôle imagerie, AP-HM & CERIMED, Aix-Marseille Université)
Equipe 8 : CRMBM/CEMEREM (Pr P. Cozzone, Drs V. Callot, M. Guye, Pôle imagerie, AP-HM & CNRS UMR 6612 - CERIMED, Aix-Marseille Université)
Equipe 9 : CRO2, Plateforme PIT2 (Dr D. Lafitte, UMR Inserm 911, Aix-Marseille Université)
Equipe 10 : CRO2, Equipe 4 « Angiogenèse, invasivité et microenvironnement tumoral » (Prs L’H. Ouafik and D. Figarella-Branger, UMR Inserm 911, Aix-Marseille Université)
Equipe 11 : CRO2, Equipe 2 « Microenvironnement redox, cytosquelette et progression tumorale » (Prs H. Kovacic and V. Peyrot, UMR Inserm 911, Aix-Marseille Université)
Equipe 12 : CRO2, Equipe 1 « Communications Microtubules-mitochondrie : implications en oncopharmacologie » (Pr D. Braguer, UMR Inserm 911, Aix-Marseille Université)
Equipe 13 : ImaPath INT (Drs G. Rougon and F. Debarbieux, Aix-Marseille Université & CERIMED)
Equipe 14 : Service de Physiopathologie et Neurophysiologie, UMR751 (Pr P. Chauvel, A. Trebuchon)
Equipe 15 : Service de Radiothérapie (Pr D. Cowen, Dr L. Padovani, Pôle imagerie, AP-HM)
Equipe 16 : Service de Neurooncologie (Pr O. Chinot, Dr M. Barrie, C. Boucard, Pôle Oncologie, AP-HM)
Equipe 17 : Service d’Oncologie Pédiatrique (Pr G. Michel, Drs JC. Gentet and N. André, Pôle de pédiatrie, AP-HM)
Equipe 18 : EA3279 (Pr P. Auquier, Aix-Marseille Université)

En gras, l’investigateur principal de chaque équipe

Liste des essais cliniques en cours

Les équipes


Dominique Figarella-Branger
P. Metellus
D. Scavarda
N. Girard
E. Guedj
V. Callot, M. Guye
L’H. Ouafik
Hervé Kovacic
Diane Braguer
G. Rougon, F. Debarbieux
A. Trebuchon
L. Padovani
O. Chinot
N. André
* Pascal Auquier

Les plateformes

Biobank
Laboratoire de Transfert
Plateforme PIT2

Les publications

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm et al. Cell, 2016 ;164(5):1060-72.

Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signalling

Figarella-Branger et al. Neuro Oncol, 2016 Mar 15. (Epub ahead of print).

Molecular heterogeneity of glioblastomas : does location matter ?

Denicolai et al. Oncotarget, 2016 ;7(1):902-13.

Negative of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3

Velot et al. Oncotarget, 2015 ;6(41):43557-70.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma

Tabouret et al. Eur J Surg Oncol, 2015 ;41(12):1685-90.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the
BEVERLY-2 study

Tabouret et al. Oncotarget, 2016 Feb 23. (Epub ahead of print).

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma : comprehensive safety results during and after first-line therapy
Saran et al. Neuro Oncol, 2016 Jan 24 (Epub ahead of print).

The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary
Louis et al. Acta Neuropathol, 2016 ;131(6):803-20.

Future paradigms for precision oncology
Klement et al. Oncotarget, 2016 May 19 (Epub ahead of print).

Integrated genomic analysis of oligodendroglial tumours identifies subgroups of 1p/19q co-deleted oligodendrogliomas
Kamoun et al. Nat Commun, 2016 7:11263.

Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma ?
Heng et al. Cancer Med, 2016 Mar 31 (Epub ahead of print).

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma ? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Happold et al. J Clin Oncol, 2016 ;34(7):731-90.

Mitotic index, microvascular proliferation and necrosis define three pathological subgroups of prognostic relevance among 1p/19q co-deleted Anaplastic Oligodendrogliomas
Figarella-Branger et al. Neuro Oncol, 2016 ;18(6):888-90.

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy : an exploratory analysis of AVAglio
Chinot et al. Neuro Oncol, 2016 Mar 22 (Epub ahead of print).

Computational oncology - mathematical modelling of drug regimens for precision medicine
Barbolosi et al. Nat Rev Clin Oncol, 2016 ;13(4):242-54.

Pilot evaluation of physical and psychological effects of a physical trek programme including a dog sledding expedition in children and teenagers with cancer
Vallet et al. Ecancermedicalscience, 2015 ;9:558.

LRP1B deletion is associated with poor outcome for glioblastoma patients
Tabouret et al. J Neurol Sci, 2015 ;358(1-2):440-3.

Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy
Rakotonjanahary et al. PLoS One, 2015 ;10:e0127676.

Prognostic relevance of histomolecular classification of diffuse adult high grade gliomas with necrosis
Figarella-Branger et al. Brain Pathol, 2015 Jul ;25(4):418-28.

Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma
Chastegner et al. Cancer Chemother Pharmacol, 2015 ;76(2):425-32.

Neuro-oncological patients admitted in intensive-care unit : predictive factors and functional outcome
Tabouret et al. J Neurooncol, 2016 ;127(1):111-7.

Phenotypic dynamics of microglial and monocyte-derived cells in GBM-bearing mice
Ricard et al. Sci Rep, 2016 ;6:26381.

The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types
Koob et al. J Neurooncol, 2016 ;127(2):345-53.

Innovative mouse models for imaging neuroinflammation
Caravagna et al. Current protocols in mouse biology, 2016 in press.

Ultrapure laser-synthesized Si-based nanomaterials for biomedical applications : in vivo assessment of safety and biodistribution
Baati et al. Sci Rep, 2016 May 6 ;6:25400.

Stathmin potentiates vinflunine and inhibits paclitaxel activity
Malesinski et al. PLoS One, 2015 Jun 1 ;10(6).

An ultrasensitive LC-MS/MS method with liquid phase extraction to determine Paclitaxel in both cell culture medium and lysate promising quantification of drug nanocarriers release in vitro
Baati et al. J Pharm Biomed Anal, J Pharm Biomed Anal, 2015 ;115:300-6.

9p21.3 allelic loss is a prognostic factor in 1p/19q co-deleted anaplastic gliomas
Alentorn et al. Neurology, 2015 Oct 13 ;85(15):1325-31.

Hypoxia Associated Factor expression in low grade gliomas : a marker of poor outcome
Tchoghandjian et al. Oncotarget, 2016 Mar 14. doi : 10.18632/oncotarget.8046.

Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma
Taphoorn et al. J Clin Oncol, 2015 May 26. pii : JCO.2014.60.3217.

Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
Tabouret et al. Oncotarget, 2015 May 10 ;6(13):11664-75.

MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high grade glioma
Tabouret et al. Neuro-Oncology, 2015 Aug ;17(8):1174-6.

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen
Tabouret et al. Anticancer research, 2015 May ;35(5):2901-8.

Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide : retrospective analysis of the AVAglio trial.
Sandmann et al. J Clin Oncol, 2015 Sep 1 ;33(25):2735-44.

Phase I dose-escalation study of the anti-placental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
Labssen et al. Neuro-Oncol, 2015 ; Jul ;17(7):1007-15.

TCF12 is mutated in anaplastic oligodendroglioma
Labreche et al. Nat Commun, 2015 ; Jun 12 ;6:7207.

AM blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signaling
Khalfaoui-Bendriss et al. Oncotarget, 2015 ; Apr 10 ;6(10):7536-53.

chordoid gliomas of the third ventricle share TTF-1 expression with organum vasculosum of the lamina terminalis
Bielle et al. Am J Surg Pathol, 2015 ; Jul ;39(7):948-56 .

Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France
Zouaoui et al. Neurosurg Rev, 2014 ; Jul ;37(3):415-23 ; discussion 423-4.

Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB
Tchoghandjian et al. Cell Death Differ, 2014 ; May ;21(5):735-47.

Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth
Serres et al. Oncogene, 2014 ; Jun 26 ;33(26):3451-62.

Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression
Reyes et al. Neuro Oncol, 2014 ; May ;16(5):662-70.

Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumors
Nguyen et al. Neuropathol Appl Neurobiol, 2014 ; Apr ;41(3):403-8.

Assessing the quality of life among caregivers of patients with glioma
Minaya Flores et al. Neurooncol Pract, 2014 ; Dec ;1(4):191-197.

National network of paediatric central nervous system tumours reviewing by the Groupe d’Étude de Neuropathologie Oncologique Pediatrique (GENOP)
Meyronet et al. Ann Pathol, 2014 ; Feb ;34(1):74-86.

French research infrastructures to develop and validate glioma biomarkers
Menei et al. Neurosurgery, 2014 ; Aug ;75(2):E195-6.

International Society Of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading
Louis et al. Brain Pathol, 2014 ; Sep ;24(5):429-35.

ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway : implication in cancer cell response to microtubule-targeting agents
Le Grand et al. Oncotarget, 2014 ; May 30 ;5(10):3408-23.

Ex vivo cultures of glioblastoma in 3-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening
Jiguet-Jiglaire et al. Exp Cell Res, 2014 ; Feb 15 ;321(2):99-108.

Prognostic relevance of histomolecular classification of diffuse adult high grade gliomas with necrosis
Figarella-Branger et al. Brain Pathology, 2014 ; Nov 18. doi : 10.1111/bpa.12227.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide
Etcheverry et al. Plos One , 2014 ; Sep 18 ;9(9):e104455.

Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo
Denicolaï et al. Oncotarget, 2014 ; Nov 15 ;5(21):10934-48.

POLA network : a national network for high-grade oligodendroglial tumors
Delattre et al. Rev Neurol, 2014 ; Nov ; 170(11):643-5.

Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France
Darlix et al. J Neurooncol, 2014 ; Dec ;120(3):547-55.

Gold nanoparticles prepared by laser ablation in aqueous biocompatible solutions : assessment of safety and biological identity for nanomedicine applications
Correard et al. Int J Nanomed, 2014 ; Nov 21 ;9:5415-30.

Cilengitide in glioblastomas : when did it fail
Chinot et al. Lancet Oncol, 2014 ; Sep ;15(10):1044-5.

The future of antiangiogenic treatment in glioblastoma
Chinot and Reardon. Curr Opin Neurol, 2014 ; Dec ;27(6):675-82.

Bevacizumab for newly diagnosed glioblastoma
Chinot et al. N Engl J Med, 2014 ; May 22 ;370(21):2049.

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
Chinot et al. N Engl J Med, 2014 ; Feb 20 ;370(8):709-22.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma : final results of the TEMAVIR study from ANOCEF
Chauffert et al. Ann Oncol, 2014 Jul ;25(7):1442-7.

Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas : Evidence that miR200a-3p is regulated by O(6)-methylguanine methyltransferase and promotes temozolomide responsiveness
Berthois et al. Cancer Biol Ther, 2014 ; Jul ;15(7):938-50.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo
Berges et al. Oncotarget, 2014 ; Dec 30 ;5(24):12769-87.

Metronomics : towards personalized chemotherapy
André et al. Nat Rev Clin Oncol, 2014 ; Jul ;11(7):413-31.

A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth
Alves et al. Biochim Biophys Acta, 2014 ; Aug ;1838(8):2087-98.

MALDI imaging and in source decay for top down characterization of glioblastoma
Ait Belkacem et al. Proteomics, 2014 ; May ;14(10):1290-301.

Monitoring therapeutic monoclonal antibodies in brain tumor
Ait Belkacem et al. MAbs, 2014 ;6(6):1385-93. doi : 10.4161/mabs.34405.

Metronomics : towards personalized chemotherapy ?
André et al, Nat Rev Clin Oncol 2014 Jul ;11(7):413-31.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo
Denicolaï and Baeza-Kallee et al.Oncotarget 2014 Nov 15 ;5(21):10934-48.

Prognostic relevance of histomolecular classification of diffuse adult high grade gliomas with necrosis
Figarella-Branger et al.Brain Pathology 2014 Nov 18. doi : 10.1111/bpa.12227.

AM blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signaling
Khalfaoui-Bendriss et al. Oncotarget, 2015

Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumors
Nguyen and Colin et al., Neuropathol Appl Neurobiol Nov 12. doi : 10.1111/nan.12196.

Predictive biomarkers investigated in glioblastoma
Tabouret et al. Expert Rev Mol Diagn 2014 Sep ;14(7):883-93

Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
Tabouret et al. Oncotarget 2014

New IDH1 I113T mutation associated with BRAF V600E mutation : New driver of gliomagenesis ?
Tabouret E, et al. J Neurol Sci. 2014 Jul 15 ;342(1-2):204-6.

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
Tabouret E, et al. Neuro Oncol. 2014 ;16(3):392-9

An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy
Ricard C, et al. J Vis Exp. 2014 ;(86) (in press)

Six-color intravital two-photon imaging of brain tumors and their dynamic microenvironment
Ricard C and Debarbieux F. Front Cell Neurosci. 2014 Feb 24 ;8:57

Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density
Ricard C, et al. PLoS One. 2013 ;8(9) (in press)

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
Laffaire J, et al. Biomed Res Int. 2014, 2014:282815.

Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
Figarella-Branger D, et al. Neuro Oncol. 2014 Apr 9. [Epub ahead of print]

Bevacizumab for newly diagnosed glioblastoma
Chinot OL, et al. N Engl J Med. 2014 ;370(21):2049

Ex vivo cultures of glioblastoma in 3-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening.
Jiguet-Jiglaire C, et al., Exp. Cell Res. 2014 Feb 15 ;321(2):99-108.

MALDI imaging and in source decay for top down characterization of glioblastoma.
Ait Belkacem R, et al Proteomics 2013 Dec 23. doi : 10.1002/pmic.201300329

Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
Chappé C, et al. Brain Pathol. 2013 ;23(5):574-83.

Glial and glioneuronal tumors in adults and children : main genetic alterations and towards a histomolecular classification.
Figarella-Branger D, et al. Bull Cancer. 2013 ;100(7-8)

An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy
Ricard C, et al. J Visualized Exp. 2014 Apr 21 ;(86).

Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.
Rovini A, et al. PLoS One. 2013 ;8(6)

Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density
Ricard C, et al. PLoS One. 2013 Sep 12 ;8(9):e72655.

Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E, et al. J Neurooncol. 2013 ;114(2):191-8.

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
Mercurio S, et al. Acta Neuropathol Commun. 2013 ;1(1):17.

A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth
Alves et al.
Biochim Biophys Acta, 2014 Aug ;1838(8):2087-98.

Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas : Evidence that miR200a-3p is regulated by O(6)-methylguanine methyltransferase and promotes temozolomide responsiveness
Berthois et al.
Cancer Biol Ther 2014 Apr 22 ;15(7).

Gold nanoparticles prepared by laser ablation in aqueous biocompatible solutions : assessment of safety and biological identity for nanomedicine applications
Correard et al.
Int J Nanomed, 2014

ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway : implication in cancer cell response to microtubule-targeting agents
Le Grand et al.
Oncotarget, 2014 May 30 ;5(10):3408-23.

PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells
Morjen et al.
Matrix Biol, 2013 Jan ;32(1):52-62

PDF - 238 ko
Newsletter 12/2013
PDF - 190.7 ko
Newsletter 04/2014
PDF - 471.1 ko
Newsletter 9/14
PDF - 219.5 ko
Newsletter 2/15
Partenaires SIRIC